Research Progress in Clinical Diagnosis and Treatment of Immune Checkpoint Inhibitor-associated Myocarditis
10.3969/j.issn.1000-3614.2025.02.014
- VernacularTitle:免疫检查点抑制剂相关心肌炎的临床诊治进展
- Author:
Jingjing YAN
1
;
Shaoyu LIU
1
;
Hongxia GE
1
;
Qingbian MA
1
Author Information
1. 北京大学第三医院 急诊科 分子心血管学教育部重点实验室,北京 100191
- Publication Type:Journal Article
- Keywords:
immune checkpoint inhibitor;
myocarditis;
immune-related adverse event;
cardiac toxicity
- From:
Chinese Circulation Journal
2025;40(2):197-202
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors(ICI)are monoclonal antibodies that could restore and improve the ability of T lymphocytes to specifically recognize and kill tumor cells by inhibiting immune checkpoint activity,this therapeutic strategy is a breakthrough in the treatment of malignant solid tumors in recent years.ICI-associated myocarditis(ICI-M)is one of the immune-related adverse events with rapid onset,severe symptoms and rapid progression.However,the clinical understanding of ICI-M is insufficient at present.This article reviews current research progress on epidemiology,pathogenic mechanism,diagnosis and treatment of ICI-M.
